- Home
- CRSP vs KMPR Comparison
CRSP vs KMPR Comparison
Compare CRSP & KMPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRSP
- KMPR
- Stock Information
- Founded
- CRSP 2013
- KMPR 1990
- Country
- CRSP Switzerland
- KMPR United States
- Employees
- CRSP N/A
- KMPR N/A
- Industry
- CRSP Biotechnology: Biological Products (No Diagnostic Substances)
- KMPR Property-Casualty Insurers
- Sector
- CRSP Health Care
- KMPR Finance
- Exchange
- CRSP Nasdaq
- KMPR Nasdaq
- Market Cap
- CRSP 4.9B
- KMPR 4.2B
- IPO Year
- CRSP 2016
- KMPR N/A
- Fundamental
- Price
- CRSP $57.68
- KMPR $60.48
- Analyst Decision
- CRSP Buy
- KMPR Strong Buy
- Analyst Count
- CRSP 16
- KMPR 4
- Target Price
- CRSP $70.73
- KMPR $78.25
- AVG Volume (30 Days)
- CRSP 3.7M
- KMPR 581.7K
- Earning Date
- CRSP 08-04-2025
- KMPR 08-05-2025
- Dividend Yield
- CRSP N/A
- KMPR 2.13%
- EPS Growth
- CRSP N/A
- KMPR N/A
- EPS
- CRSP N/A
- KMPR 5.35
- Revenue
- CRSP $37,675,000.00
- KMPR $4,689,100,000.00
- Revenue This Year
- CRSP $28.31
- KMPR $3.29
- Revenue Next Year
- CRSP $268.05
- KMPR $12.29
- P/E Ratio
- CRSP N/A
- KMPR $11.26
- Revenue Growth
- CRSP N/A
- KMPR N/A
- 52 Week Low
- CRSP $30.04
- KMPR $53.57
- 52 Week High
- CRSP $71.13
- KMPR $73.01
- Technical
- Relative Strength Index (RSI)
- CRSP 52.32
- KMPR 42.54
- Support Level
- CRSP $61.13
- KMPR $59.82
- Resistance Level
- CRSP $69.58
- KMPR $62.47
- Average True Range (ATR)
- CRSP 3.89
- KMPR 1.07
- MACD
- CRSP -0.71
- KMPR -0.13
- Stochastic Oscillator
- CRSP 28.46
- KMPR 24.87
About CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About KMPR Kemper Corporation
Kemper Corp is a diversified insurance company that provides services in property and casualty insurance, along with life and health insurance. The company's property and casualty segment offers personal and commercial lines for home and automotive products. The company conducts its operations through two operating segments: Specialty Property & Casualty Insurance, and Life Insurance.